353 related articles for article (PubMed ID: 25376259)
1. Outsourcing cytological samples to a referral laboratory for EGFR testing in non-small cell lung cancer: does theory meet practice?
Vigliar E; Malapelle U; Bellevicine C; de Luca C; Troncone G
Cytopathology; 2015 Oct; 26(5):312-7. PubMed ID: 25376259
[TBL] [Abstract][Full Text] [Related]
2. Molecular testing in lung cancer: fine-needle aspiration specimen adequacy and test prioritization prior to the CAP/IASLC/AMP Molecular Testing Guideline publication.
Rafael OC; Aziz M; Raftopoulos H; Vele OE; Xu W; Sugrue C
Cancer Cytopathol; 2014 Jun; 122(6):454-8. PubMed ID: 24723383
[TBL] [Abstract][Full Text] [Related]
3. Detection of an EGFR mutation in cytological specimens of lung adenocarcinoma.
Mohar B; Smojver Ježek S; Rajković Molek K; Štemberger C; Kurpis M; Kupanovac Ž; Samaržija M; Jonjić N; Grahovac B
Cytopathology; 2016 Dec; 27(6):444-451. PubMed ID: 26990359
[TBL] [Abstract][Full Text] [Related]
4. EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology.
Thomas De Montpréville V; Ghigna MR; Lacroix L; Lemoine A; Besse B; Mercier O; Fadel É; Dorfmuller P; Le Chevalier T;
Pathol Res Pract; 2017 Jul; 213(7):793-798. PubMed ID: 28554746
[TBL] [Abstract][Full Text] [Related]
5. EGFR, KRAS, BRAF and HER2 testing in metastatic lung adenocarcinoma: Value of testing on samples with poor specimen adequacy and analysis of discrepancies.
Forest F; Stachowicz ML; Casteillo F; Karpathiou G; Gouzy-Grosjean F; Guilaubey C; Cottier M; Beal J; Clemenson A; Péoc'h M
Exp Mol Pathol; 2017 Dec; 103(3):306-310. PubMed ID: 29175303
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study.
Krawczyk P; Ramlau R; Chorostowska-Wynimko J; Powrózek T; Lewandowska MA; Limon J; Wasąg B; Pankowski J; Kozielski J; Kalinka-Warzocha E; Szczęsna A; Wojas-Krawczyk K; Skroński M; Dziadziuszko R; Jaguś P; Antoszewska E; Szumiło J; Jarosz B; Woźniak A; Jóźwicki W; Dyszkiewicz W; Pasieka-Lis M; Kowalski DM; Krzakowski M; Jassem J; Milanowski J
J Cancer Res Clin Oncol; 2015 Jan; 141(1):61-8. PubMed ID: 25086987
[TBL] [Abstract][Full Text] [Related]
7. EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.
Malapelle U; Bellevicine C; De Luca C; Salatiello M; De Stefano A; Rocco D; de Rosa N; Vitiello F; Russo S; Pepe F; Iaccarino A; Micheli P; Illiano A; Carlomagno C; Piantedosi FV; Troncone G
Cancer Cytopathol; 2013 Oct; 121(10):552-60. PubMed ID: 23780873
[TBL] [Abstract][Full Text] [Related]
8. FNA smears as a potential source of DNA for targeted next-generation sequencing of lung adenocarcinomas.
Treece AL; Montgomery ND; Patel NM; Civalier CJ; Dodd LG; Gulley ML; Booker JK; Weck KE
Cancer Cytopathol; 2016 Jun; 124(6):406-14. PubMed ID: 26882436
[TBL] [Abstract][Full Text] [Related]
9. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing.
Rekhtman N; Brandt SM; Sigel CS; Friedlander MA; Riely GJ; Travis WD; Zakowski MF; Moreira AL
J Thorac Oncol; 2011 Mar; 6(3):451-8. PubMed ID: 21266922
[TBL] [Abstract][Full Text] [Related]
10. Morphologic Accuracy in Differentiating Primary Lung Adenocarcinoma From Squamous Cell Carcinoma in Cytology Specimens.
Zakowski MF; Rekhtman N; Auger M; Booth CN; Crothers B; Ghofrani M; Khalbuss W; Laucirica R; Moriarty AT; Tabatabai ZL; Barkan GA
Arch Pathol Lab Med; 2016 Oct; 140(10):1116-20. PubMed ID: 27552093
[TBL] [Abstract][Full Text] [Related]
11. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
[TBL] [Abstract][Full Text] [Related]
12. EGFR mutation testing of lung cancer patients - Experiences from Vestfold Hospital Trust.
Berg J; Fjellbirkeland L; Suhrke P; Jebsen P; Lund-Iversen M; Kleinberg L; Helgeland L; Brustugun OT; Helland Å
Acta Oncol; 2016; 55(2):149-55. PubMed ID: 26313507
[TBL] [Abstract][Full Text] [Related]
13. EGFR mutation genotyping and ALK status determination in liquid-based cytology samples of non-small cell lung cancer.
Satoh Y; Matsuo Y; Kuba T; Yamashita K; Sawano M; Tozaka S; Yamazaki H; Sonoda D; Mikubo M; Naito M; Matsui Y; Shiomi K; Yoshida T; Murakumo Y
Virchows Arch; 2020 May; 476(5):753-762. PubMed ID: 31823000
[TBL] [Abstract][Full Text] [Related]
14. [Feasibility of assessing EGFR mutation and others using samples obtained by EBUS transbronchial needle aspiration].
Boulanger S; Delattre C; Descarpentries C; Escande F; Bouchindhomme B; Copin MC; Dhalluin X; Scherpereel A; Ramon PP; Cortot A; Fournier C
Rev Mal Respir; 2013 May; 30(5):351-6. PubMed ID: 23746811
[TBL] [Abstract][Full Text] [Related]
15. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis.
Nicholson AG; Gonzalez D; Shah P; Pynegar MJ; Deshmukh M; Rice A; Popat S
J Thorac Oncol; 2010 Apr; 5(4):436-41. PubMed ID: 20068475
[TBL] [Abstract][Full Text] [Related]
16. The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies.
Ho HL; Kao HL; Yeh YC; Chou TY
Diagn Pathol; 2019 Jun; 14(1):59. PubMed ID: 31221183
[TBL] [Abstract][Full Text] [Related]
17. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.
Proietti A; Alì G; Pelliccioni S; Lupi C; Sensi E; Boldrini L; Servadio A; Chella A; Ribechini A; Cappuzzo F; Miccoli M; Fontanini G
Cancer Cytopathol; 2014 Jun; 122(6):445-53. PubMed ID: 24648382
[TBL] [Abstract][Full Text] [Related]
18. [Detection of epidermal growth factor receptor mutations in non-small-cell lung carcinoma by direct sequencing and correlations with clinicopathological characteristics and sample types].
Sun MH; Yang F; Shen L; Zhang L; Chen Y; Cai X; Zhu XL; Zhou XY
Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):655-9. PubMed ID: 22321541
[TBL] [Abstract][Full Text] [Related]
19. Subtyping and EGFR mutation testing from blocks of cytological materials, based on liquid-based cytology for lung cancer at bronchoscopic examinations.
Tanaka R; Ohtsuka K; Ogura W; Arai N; Yoshida T; Nakazato Y; Tachibana K; Takata S; Fujiwara M; Kamma H; Shibahara J; Kondo H
Diagn Cytopathol; 2020 Jun; 48(6):516-523. PubMed ID: 32125777
[TBL] [Abstract][Full Text] [Related]
20. MassARRAY, pyrosequencing, and PNA clamping for EGFR mutation detection in lung cancer tissue and cytological samples: a multicenter study.
Min KW; Kim WS; Jang SJ; Choi YD; Chang S; Jung SH; Kim L; Roh MS; Lee CS; Shim JW; Kim MJ; Lee GK;
J Cancer Res Clin Oncol; 2016 Oct; 142(10):2209-16. PubMed ID: 27535566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
